Directorate change

Board change

IP Group plc (LSE: IPO) ("the Group"), which invests in breakthrough science and technology companies with the potential to create a better future for all, announces that, in accordance with UK Listing Rule 6.4.9(2), it has received notification from Sir Douglas Flint, CBE, Chair of IP Group, that he will join the Board of Prudential plc as independent non-executive director, and Chair designate, with effect from March 2026.

As a result, Sir Douglas Flint has confirmed his intention to retire as a Director and Chair of IP Group at the conclusion of the Group's Annual General Meeting in June 2026 and will therefore not stand for re-election.

As outlined in the Notice of the 2025 AGM, the Board's Nomination Committee has been planning succession to ensure a suitable sequencing of transition given that a number of directors, including the Chair, are approaching the nine year maximum term and has been prioritising the Chair succession as part of this. This process is ongoing and the Group will provide a further update in due course.

For more information, please contact:

Notes for editors

About IP Group

IP Group accelerates the impact of science for a better future. As the most active UK based, early stage science and technology investor, we develop and support some of the world's most exciting businesses in healthtech, deeptech and cleantech. Through Parkwalk, the UK's largest growth EIS fund manager, we also back world-changing innovation emerging in leading universities and research institutions. Our specialist investment team combines sector expertise with an international approach. Together we have a strong track record of success, having backed high-profile companies including Oxford Nanopore Technologies plc, Hinge Health, Featurespace, First Light Fusion, Hysata, and Oxa. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

For more information, please visit our website at www.ipgroupplc.com.

ENDS